

SANTHERA PHARMACEUTICALS HOLDING AG

ISIN: CH1276028821 WKN: 127602882

Overview

| | |
|---------------------|---|
| 2024/08/21 17:31:52 | |
| Price | 8.99 CHF |
| Difference | ▲ 1.58% (0.14) |

| General attributes | |
|--------------------|------------------------------------|
| ISIN | CH1276028821 |
| Symbol | SANN |
| Exchange | SIX Swiss Exchange |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 111 EUR |
| Benchmark | SWISS MARKET INDEX |

| Market data | |
|-------------------|------------------|
| Bid (Bid size) | 8.99 CHF (20) |
| Ask (Ask size) | 9.00 CHF (1,300) |
| Open | 8.90 CHF |
| High | 9.00 CHF |
| Low | 8.76 CHF |
| Close (prev. day) | 8.85 CHF |
| VWAP | 8.935024 CHF |
| Volume (pcs) | 6,559 |
| Trading volume | 58,604.82 |
| Number of trades | 65 |
| Last size | 64 |

| Futures and Options | |
|---------------------|---|
| Related Futures | - |
| Related Options | - |

| PDF Downloads | |
|---|--------------------------|
| Company report: SANTHERA PHARMACEUTICALS HOLDING AG | Download |



Information about previous performance does not guarantee future performance. Source: FactSet

Recent research

| on sector | | on market | |
|------------|--|-----------------------|--------------------------|
| Date | | Headline | Download |
| 2024/08/12 | | Global Equity Ratings | Download |
| 2024/07/24 | | Global Equity Ratings | Download |
| 2024/07/12 | | Global Equity Ratings | Download |
| 2024/06/21 | | Global Equity Ratings | Download |
| 2024/06/14 | | Global Equity Ratings | Download |

Details

2024/08/21 17:31:52

Price

8.99 CHF

Difference ▲ 1.58% (0.14)

General attributes

| | |
|----------------|------------------------------------|
| ISIN | CH1276028821 |
| Symbol | SANN |
| Exchange | SIX Swiss Exchange |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 111 EUR |
| Benchmark | SWISS MARKET INDEX |

Market data

| | |
|-------------------|------------------|
| Bid (Bid size) | 8.99 CHF (20) |
| Ask (Ask size) | 9.00 CHF (1,300) |
| Open | 8.90 CHF |
| High | 9.00 CHF |
| Low | 8.76 CHF |
| Close (prev. day) | 8.85 CHF |
| VWAP | 8.935024 CHF |
| Volume (pcs) | 6,559 |
| Trading volume | 58,604.82 |
| Number of trades | 65 |
| Last size | 64 |

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|---------|---------|---------|
| Perf (%) | -11.69% | +13.80% | -55.38% |
| Perf (abs.) | -1.19 | +1.09 | -11.16 |
| Beta | 0.60 | 0.52 | -0.08 |
| Volatility | 46.47 | 61.04 | 75.44 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 8.86 CHF (11,397) |
| Ø price 30 days Ø volume 30 days (pcs.) | 8.92 CHF (16,606) |
| Ø price 100 days Ø volume 100 days (pcs.) | 9.22 CHF (19,331) |
| Ø price 250 days Ø volume 250 days (pcs.) | 9.46 CHF (36,764) |
| YTD High date | 11.44 CHF (2024/02/26) |
| YTD Low date | 8.10 CHF (2024/06/25) |
| 52 Weeks High date | 14.62 CHF (2023/10/27) |
| 52 Weeks Low date | 7.14 CHF (2023/10/11) |

All listings for SANTHERA PHARMACEUTICALS HOLDING AG

| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
|------------------------|------------|-------|-------------|-----------------------|------------------|
| Stuttgart | - | - | - | 0.00 | - |
| SIX Swiss Exchange | 2024/08/21 | 17:31 | 8.99 CHF | 0.06 | 65 |
| London Stock Exchange | 2021/06/11 | 13:10 | 29.1736 CHF | 0.00 | 1 |
| Frankfurt | 2019/06/28 | 08:04 | 136.40 EUR | 0.00 | 2 |
| FINRA other OTC Issues | 2024/02/22 | 18:23 | 11.70 USD | 0.01 | 2 |

Berlin

2019/06/ 15:59 137.20 EUR 0.00
28

5

Company profile

Company Logo



Contact Details

SANTHERA PHARMACEUTICALS
HOLDING AG

--

Hohenrainstrasse 24 - 4133 Pratteln

Telefon: +41-61-906-89-50

Fax: +41-61-906-89-51

E-mail: office@santhera.com

PDF Downloads

Company report: SANTHERA
PHARMACEUTICALS HOLDING AG



Company Profile

Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.

Members of Management Board

Dario Eklund Chairman of Managing Board

Ana Vera Member of Executive Committee

Andrew Smith Member of Executive Committee

Geert Jan van Daal Member of Executive Committee

Günther Metz Member of Executive Committee

Neville Kodkani Member of Executive Committee

Oliver Kronenberg Member of Executive Committee

Andreas Missy Member of Executive Committee

Marc Schrader Member of Executive Committee

Oliver Strub Member of Executive Committee

Sabine Pilot Member of Executive Committee

Sarah Holmes-Klotz Member of Executive Committee

Board of directors

Otto Schwarz Member of the administrative board

Shabir Hasham Member of the administrative board

Bradley Meyer Member of the administrative board

Philipp Gutzwiller Member of the administrative board

Thomas Meier Chairman of the administrative board